Sun Pharma Advanced Research Company (SPARC), the pharma research and drug discovery arm of Sun Pharma today reported widening of standalone net loss to Rs 36.41 crore for the first quarter ended June 30.
The company had posted a net loss of Rs 1.65 crore for the corresponding period of the previous fiscal, SPARC said in a BSE filing.
Standalone total income from operations of the company for the quarter under consideration also decreased to Rs 21.48 crore as against Rs 43.44 crore for the same period year ago.
Shares of Sun Pharma Advanced Research Company closed 3.70 per cent lower at Rs 361.80 on BSE.
